Develops genomic tests for thyroid cancer diagnosis.
Jun 2026Revenue $36.1M/yrExpenses $32.0M/yr
Reached break-even May 2023
Figures by year
When did Interpace Biosciences become profitable?
Its revenue passed its expenses in May 2023. In the 12 months to Jun 2026, revenue was $36.1M and expenses $32.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $38.7M | $34.6M | $4.08M |
| Dec 2024 | $46.9M | $38.8M | $8.11M |
| Dec 2023 | $40.0M | $36.1M | $3.96M |
| Dec 2022 | $31.8M | $35.5M | −$3.62M |
| Dec 2021 | $33.1M | $39.5M | −$6.34M |
| Dec 2020 | $32.4M | $58.5M | −$26.1M |
| Dec 2019 | $24.2M | $50.7M | −$26.4M |
| Dec 2018 | $21.9M | $34.5M | −$12.6M |
| Dec 2017 | $15.9M | $22.2M | −$6.29M |
| Dec 2016 | $13.1M | $19.5M | −$6.44M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.